Psilocybin reduces symptoms of major depression: The Lancet

Published Date: 04 Mar 2023

A new study by Robin von Rotz and his team found that moderate doses of psilocybin for at least two weeks reduced symptoms of depression...

Read Full News

Latest News

FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion

FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Improving CRC Screening Rates With High-Quality, Noninvasive Tests, with Keith Winfrey, MD, MPH Keith Winfrey, MD, MPH

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

ACP Urges Concern for Health Policy Issues, with Shari Erickson, MPH Shari Erickson, MPH

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

Reviving exhausted immune cells boosts tumor elimination

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Precision therapy could stop breast cancer at the source

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of ...

Todays Updates

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient Noah Stansfield

The therapy also received orphan drug designation from the FDA.

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

HCPLive 5 Stories in Under 5: Week of 01/11

HCPLive 5 Stories in Under 5: Week of 01/11

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Todays Updates

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient Noah Stansfield

The therapy also received orphan drug designation from the FDA.

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

HCPLive 5 Stories in Under 5: Week of 01/11

HCPLive 5 Stories in Under 5: Week of 01/11

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Latest News

FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion

Increases in Physician Attrition Rates Could Worsen Shortages

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of ...

News All Time

Cellular protein FGD3 boosts breast cancer chemotherapy and immunotherapy, study finds

A naturally-occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a ...

Global reviews call for urgent action on endometriosis in most world regions

Two reviews published in The Lancet Obstetrics, Gynecology & Women's Health reveal stark global inequities in how endometriosis is recognized, treated, and prioritized in national health systems.

Mental and physical coaching before surgery prepares immune system and reduces complications, trial finds

The weeks leading up to a major surgery can be a time of uncertainty and worry for patients, many of whom anticipate the need for rehabilitation to get back on their feet. But if patients improve their physical and mental ...

Flu vaccine performance varies by age, study reveals

New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the vaccine type and age ...

Study reveals why some myeloma patients stay cancer-free for years after CAR T therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see ...

Researchers aim to disrupt breast cancer line of communication and prevent spread

Cancer Center at Illinois (CCIL) Program Leader Erik Nelson's lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics.

Study tracking how tumor microenvironment develops signals opportunity for early detection, risk prediction

Colorectal cancer precursor lesions are benign growths that can develop into colorectal cancer (CRC) over time, through either a conventional or serrated pathway. Understanding how the immune system reacts to these precursor ...

Rapid growth of radiopharmaceutical therapy highlights need for expertise

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining the education, training, and experience needed to ensure the safe and effective delivery of radiopharmaceutical therapy ...

Blood test offers hope for more effective ovarian cancer treatment

New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular treatment for ovarian cancer, known as PARP inhibitor therapy.

T cell therapies show long-term HPV gains

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center ...

FDA grants fast track designation to drug combo for colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma ...

Q&A: Connection between a distinct immune cell and colitis discovered

CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells exacerbate inflammation and lead to chronic disease in certain conditions.

Newly identified lymphoma subtype gives hope in fight against aggressive form of blood cancer

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer scientists and biologists ...

Sleep issues linked to higher risk of severe asthma in children

About 30 to 40% of children with asthma experience sleep difficulties due to symptoms like coughing and wheezing. Poor sleep increases the risk of severe asthma exacerbations (attacks) that often necessitate a hospitalization ...

What is myasthenia gravis, the rare disease tennis great Monica Seles lives with?

Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally.

Largest study on infant-type hemispheric glioma reports factors to guide treatment approaches

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment ...

Recommended News For You

Similar survival seen with simple versus radical hysterectomy for cervical cancer

Primary Sjögren's syndrome patients' B-Cell Stimulating Factors are associated with the growth of lymphomas.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

Hit and Miss for CDK4/6 Inhibitor in Recurrent Brain Cancer

Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

An Intimate Life of Medical Innovation and Charity.

Recommended Articles For You

Neutrophil Profiling and AI Rewrites Cancer Diagnosis 

Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership 

Gut microbiota in curing cancer 

Examining Serum Osmolality: What It Is And How To Test For It 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

2.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

3.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

4.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

5.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

1.

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA

2.

CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies

3.

Tazemetostat: A Promising New Treatment for Cancer

4.

Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization

5.

Understanding QSOFA: A Vital Tool for Recognizing Sepsis 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

2.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot